You just read:

Janssen Submits Application to U.S. FDA Seeking Approval of New DARZALEX® (daratumumab) Subcutaneous Formulation

News provided by

The Janssen Pharmaceutical Companies of Johnson & Johnson

Jul 12, 2019, 11:48 ET